Long-Term Use of PLD Linked to Risk of Secondary Cancer

Pegylated Liposomal Doxorubicin, or PLD, is the common treatment for platinum-sensitive and platinum-resistant recurrent epithelial ovarian cancer. According to recent data presented at the 2011 Annual Meeting for the American Society of Clinical Oncology, long-term use of PLD may carry with it an increased risk of developing secondary cancer of the oral cavity. Dr. Timothy [...]